Center for Liver DiseaseDepartment of MedicineInova Fairfax Medical CampusFalls ChurchVirginiaUSA.
Inova MedicineBeatty Liver and Obesity Research ProgramInova Health SystemFalls ChurchVirginiaUSA.
Hepatol Commun. 2022 Oct;6(10):2860-2866. doi: 10.1002/hep4.2048. Epub 2022 Jul 26.
Patients with preexisting chronic liver disease (CLD) may experience a substantial burden from both coronavirus 2019 (COVID-19) infection and pandemic-related life disruption. We assessed the impact of the COVID-19 pandemic on patients with CLD. Patients enrolled in our Global Liver Registry were invited to complete a COVID-19 survey. As of June 2021, 2500 patients (mean age ± SD, 49 ± 13 years; 53% men) from seven countries completed the survey. Of all survey completers, 9.3% had COVID-19. Of these patients, 19% were hospitalized, 13% needed oxygen support, but none required mechanical ventilation. Of all patients including those not infected with COVID-19, 11.3% reported that the pandemic had an impact on their liver disease, with 73% of those reporting delays in follow-up care. The Life Disruption Event Perception questionnaire confirmed worsening in at least one area (food/nutrition, exercise, social life, vocation/education, financial situation, housing, or health care) in 81% and 69% of patients with and without a history of COVID-19, respectively (p = 0.0001). On a self-assessed Likert health score scale (range, 1-10; 10 indicates perfect health), patients with a COVID-19 history scored lower (mean ± SD, 6.7 ± 2.2 vs. 7.4 ± 2.2, respectively; p < 0.0001) despite reporting similar health scores if there was no pandemic (mean ± SD, 8.5 ± 1.4 vs. 8.4 ± 1.6, respectively; p = 0.59). After adjustment for country of enrollment, liver disease etiology and severity, age, sex, body mass index, diabetes, and history of psychiatric comorbidities, COVID-19 was found to be independently associated with lower self-assessed health scores (beta = -0.71 ± 0.14; p < 0.0001). The COVID-19 pandemic resulted in a substantial burden on the daily life of patients with CLD.
患有慢性肝病(CLD)的患者可能会因 2019 年冠状病毒(COVID-19)感染和大流行相关的生活中断而承受巨大负担。我们评估了 COVID-19 大流行对 CLD 患者的影响。邀请我们全球肝脏登记处的患者完成 COVID-19 调查。截至 2021 年 6 月,来自七个国家的 2500 名患者(平均年龄±标准差,49±13 岁;53%为男性)完成了调查。所有完成调查的患者中,有 9.3%感染了 COVID-19。在这些患者中,19%住院,13%需要吸氧支持,但没有需要机械通气的患者。包括未感染 COVID-19 的患者在内,所有患者中有 11.3%报告称大流行对他们的肝病产生了影响,其中 73%的患者报告说随访护理延迟。生活干扰事件感知问卷证实,在至少一个方面(食物/营养、运动、社交生活、职业/教育、财务状况、住房或医疗保健)恶化的患者分别为 81%和 69%,有和没有 COVID-19 病史的患者(p=0.0001)。在自我评估的李克特健康评分量表(范围,1-10;10 表示完美健康)上,COVID-19 病史患者的评分较低(平均±标准差,6.7±2.2 与 7.4±2.2,分别;p<0.0001),尽管如果没有大流行,他们报告的健康评分相似(平均±标准差,8.5±1.4 与 8.4±1.6,分别;p=0.59)。在校正登记国家、肝病病因和严重程度、年龄、性别、体重指数、糖尿病和精神共病病史后,发现 COVID-19 与较低的自我评估健康评分独立相关(β=-0.71±0.14;p<0.0001)。COVID-19 大流行给 CLD 患者的日常生活带来了巨大负担。